HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
Lisa Sandmann, Cihan Yurdaydin, Katja Deterding, Benjamin Heidrich, Svenja Hardtke, Patrick Lehmann, Birgit Bremer, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, Benjamin Maasoumy, HIDIT‐II Study Group – 23 September 2021 – Standard treatment of hepatitis delta virus (HDV) infection remains pegylated‐interferon alfa (peg‐IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events.